Technical Analysis for CLBS - Caladrius Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 3.0 -3.23% -0.10
CLBS closed down 3.23 percent on Friday, May 17, 2019, on 81 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical CLBS trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish -3.23%
Bollinger Band Squeeze Range Contraction -3.23%
BB Squeeze + Upper Band Touch Range Contraction -3.23%
Up 3 Days in a Row Strength -3.23%
Up 4 Days in a Row Strength -3.23%
Upper Bollinger Band Touch Strength -3.23%

Older signals for CLBS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.
Banking Biopharmaceutical Cancer Diabetes Immunotherapy Cancer Immunotherapy Metastatic Melanoma Clinical Services Acute Myocardial Infarction Treatment Of Metastatic Melanoma
Is CLBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.65
52 Week Low 2.77
Average Volume 29,830
200-Day Moving Average 4.4574
50-Day Moving Average 3.3101
20-Day Moving Average 2.986
10-Day Moving Average 2.9785
Average True Range 0.2119
ADX 18.36
+DI 17.4828
-DI 20.717
Chandelier Exit (Long, 3 ATRs ) 2.7845
Chandelier Exit (Short, 3 ATRs ) 3.4057
Upper Bollinger Band 3.1509
Lower Bollinger Band 2.8211
Percent B (%b) 0.54
BandWidth 11.044876
MACD Line -0.0847
MACD Signal Line -0.1254
MACD Histogram 0.0407
Fundamentals Value
Market Cap 28.28 Million
Num Shares 9.43 Million
EPS -11.27
Price-to-Earnings (P/E) Ratio -0.27
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.48
Resistance 3 (R3) 3.48 3.32 3.40
Resistance 2 (R2) 3.32 3.20 3.32 3.37
Resistance 1 (R1) 3.16 3.12 3.08 3.16 3.35
Pivot Point 3.00 3.00 2.96 3.00 3.00
Support 1 (S1) 2.84 2.88 2.76 2.84 2.65
Support 2 (S2) 2.68 2.80 2.68 2.63
Support 3 (S3) 2.52 2.68 2.60
Support 4 (S4) 2.52